FREQUENCY THERAPEUTICS, INC. (FREQ): Price and Financial Metrics


-0.15 (-2.81%)

POWR Rating

Component Grades













Add FREQ to Watchlist
Sign Up

Industry: Biotech


of 476

in industry


  • FREQ scores best on the Value dimension, with a Value rank ahead of 65.56% of US stocks.
  • The strongest trend for FREQ is in Momentum, which has been heading down over the past 52 weeks.
  • FREQ ranks lowest in Sentiment; there it ranks in the 4th percentile.

FREQ Stock Summary

  • FREQ's went public 2.16 years ago, making it older than just 5.08% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 1,952.08%, Frequency Therapeutics Inc's debt growth rate surpasses 99.05% of about US stocks.
  • In terms of volatility of its share price, FREQ is more volatile than 99.76% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Frequency Therapeutics Inc are CCXI, RESN, SWTX, ACRS, and MNOV.
  • FREQ's SEC filings can be seen here. And to visit Frequency Therapeutics Inc's official web site, go to

FREQ Valuation Summary

  • FREQ's price/earnings ratio is -5; this is 113.7% lower than that of the median Healthcare stock.
  • FREQ's EV/EBIT ratio has moved up 16.9 over the prior 23 months.
  • FREQ's price/sales ratio has moved NA NA over the prior 23 months.

Below are key valuation metrics over time for FREQ.

Stock Date P/S P/B P/E EV/EBIT
FREQ 2021-08-31 7.5 1.6 -5.0 -3.3
FREQ 2021-08-30 7.6 1.6 -5.0 -3.3
FREQ 2021-08-27 7.7 1.6 -5.1 -3.4
FREQ 2021-08-26 7.6 1.6 -5.0 -3.3
FREQ 2021-08-25 7.6 1.6 -5.0 -3.3
FREQ 2021-08-24 7.5 1.6 -5.0 -3.3

FREQ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FREQ has a Quality Grade of D, ranking ahead of 8.89% of graded US stocks.
  • FREQ's asset turnover comes in at 0.147 -- ranking 225th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FREQ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 1 -0.828
2021-03-31 0.145 1 -1.583
2020-12-31 0.161 1 4.957
2020-09-30 0.145 1 0.830
2020-06-30 0.220 1 0.575
2019-12-31 0.216 1 1.319

FREQ Price Target

For more insight on analysts targets of FREQ, see our FREQ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.7 (Moderate Buy)

FREQ Stock Price Chart Interactive Chart >

Price chart for FREQ

FREQ Price/Volume Stats

Current price $5.18 52-week high $58.37
Prev. close $5.33 52-week low $5.06
Day low $5.06 Volume 124,933
Day high $5.42 Avg. volume 616,894
50-day MA $6.64 Dividend yield N/A
200-day MA $12.53 Market Cap 179.24M


Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. T

FREQ Latest News Stream

Event/Time News Detail
Loading, please wait...

FREQ Latest Social Stream

Loading social stream, please wait...

View Full FREQ Social Stream

Latest FREQ News From Around the Web

Below are the latest news stories about Frequency Therapeutics Inc that investors may wish to consider to help them evaluate FREQ as an investment opportunity.

Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 15, 2021

Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

LEXINGTON, Mass., November 15, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2021.

Yahoo | November 15, 2021

Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function, today will host a virtual R&D event. The webcast can be accessed here. We look forward to highlighting the extensive data supporting our Phase 2b study (FX-322-208) in patients with sensorineural hearing loss (SNHL), where we have seen clear clinical improve

Business Wire | November 9, 2021

Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 8, 2021

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG lifted its stake in Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 35.3% during the 2nd quarter, reports. The fund owned 25,261 shares of the company’s stock after purchasing an additional 6,596 shares during the quarter. Deutsche Bank AG’s holdings in Frequency Therapeutics were worth $252,000 at the end of the most recent quarter. […]

Dakota Financial News | October 30, 2021

Read More 'FREQ' Stories Here

FREQ Price Returns

1-mo -17.52%
3-mo -34.51%
6-mo -42.19%
1-year -81.95%
3-year N/A
5-year N/A
YTD -85.31%
2020 101.14%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6791 seconds.